KOSDAQMedia & Entertainment044480

Billions

₩2,180▼ 5.42%2026-11-18 close
Market Cap
₩14.5B
Turnover
₩65,539,960
Volume
30K
Shares out.
6.7M
PER
—
PBR
0.4×
EPS
-₩4,329
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Annual losses narrowed, but quarterly losses widened again

Billions combines condom and medical rubber manufacturing with entertainment. Annual operating losses narrowed over four years, but quarterly operating losses have continued since Q2 2026.

  1. 1

    The annual operating loss shrank from KRW 8.88 billion in 2022 to KRW 834 million in 2025, and the operating margin improved from -11.4% to -3.3%.

  2. 2

    Revenue peaked at KRW 97 billion in 2023 and then fell for two straight years, to KRW 41.7 billion in 2024 and KRW 25.3 billion in 2025.

  3. 3

    Q3 2026 revenue was KRW 4.84 billion, down 36.2% year on year, and the operating loss widened to KRW 1.04 billion.

  4. 4

    The combined net loss attributable to controlling shareholders over the last four quarters was KRW 22.7 billion, close in scale to total equity of KRW 24.5 billion at end-2025.

  5. 5

    Based on Q2 2026 sales, the business mix was reported as 55% management and 45% medical device manufacturing and sales.

02

Business structure

Billions was founded in 1973 as a maker of hygienic and medical rubber products and listed on KOSDAQ in 2001. In 2023 it acquired two entertainment companies, after which it ran condom and medical rubber sales alongside entertainment.

The company describes itself as the number one condom maker in the domestic market, and its main products are condoms, a finger-thimble product, and gloves. Gloves are divided into medical, industrial, protective, and examination types.

The manufacturing side produces condoms to international standards, with regular and specialty types and a range of colors and fragrances. The entertainment side manages artist activities and plans and produces content, including dramas, and pairs new-talent marketing with OTT content production.

An outside data set puts the Q2 2026 sales mix at 55% management and 45% medical device manufacturing and sales. Once the annual report is filed, segment sales can be checked on the same basis. The largest shareholder changed on May 21, 2024.

At the extraordinary shareholders meeting on November 6, 2026, an amendment to the articles and the election of Kim Tae-sung as an inside director both passed. The amendment also reworded the business purpose covering e-commerce.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7.6B-₩12,813,660−0.2%
2025Q4₩5.1B-₩63,541,588−1.2%
2026Q1₩7.9B₩100M1.9%
2026Q2₩6.8B-₩600M−8.6%
2026Q3₩4.8B-₩1B−21.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩78.1B-₩8.9B-₩18.4B−11.4%−65.3%61.6%
2023₩97B-₩7.5B-₩13.8B−7.7%−86.3%115.9%
2024₩41.7B-₩1.1B-₩2B−2.7%−8.9%121.8%
2025₩25.3B-₩800M-₩7.1B−3.3%−29.1%98.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue rose from KRW 78.1 billion in 2022 to KRW 97 billion in 2023, the largest year in the 2022 to 2025 period, with 2023 up 24.3% year on year. Revenue then fell for two straight years, to KRW 41.7 billion in 2024 (down 57.0%) and KRW 25.3 billion in 2025 (down 39.3%).

The operating loss was KRW 8.88 billion in 2022, KRW 7.49 billion in 2023, KRW 1.13 billion in 2024, and KRW 834 million in 2025, a loss in each of four consecutive years that narrowed every year. The operating margin read -11.4%, -7.7%, -2.7%, and -3.3%, so 2025 was slightly weaker than 2024 as revenue declined.

The net loss attributable to controlling shareholders was KRW 18.4 billion in 2022, KRW 13.8 billion in 2023, KRW 1.96 billion in 2024, and KRW 7.13 billion in 2025, which was a loss in each of four consecutive years and widened again in 2025.

Net income including non-controlling interests was KRW 8.61 billion in 2024, positive, while the loss attributable to controlling shareholders that year was KRW 1.96 billion, and the gap between the two reflects non-controlling interests.

Operating cash flow went from negative KRW 1.64 billion in 2022 and negative KRW 3.36 billion in 2023 to positive KRW 677 million in 2024 and KRW 722 million in 2025. The debt ratio rose from 61.6% in 2022 to 115.9% in 2023 and 121.8% in 2024, then fell to 98.6% in 2025.

Total equity at end-2025 was KRW 24.5 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 24.2 billion.

Quarterly revenue went from KRW 7.58 billion in Q3 2025 and KRW 5.11 billion in Q4 2025 (down 32.6% quarter on quarter) to KRW 7.89 billion in Q1 2026 (up 54.4%), then fell to KRW 6.76 billion in Q2 2026 (down 14.3%) and KRW 4.84 billion in Q3 2026 (down 28.4%), a decline over two consecutive quarters.

The operating loss was KRW 12.81 million in Q3 2025 and KRW 63.54 million in Q4 2025, then turned to operating profit of KRW 149 million in Q1 2026. Q2 2026 returned to an operating loss of KRW 580 million, and Q3 2026 widened to KRW 1.04 billion, so the loss has run for two consecutive quarters.

Net loss attributable to controlling shareholders was KRW 1.35 billion in Q3 2025 and KRW 4.49 billion in Q4 2025, and no quarterly figures are available for Q1 through Q3 2026 because those reports have not yet been filed.

The combined net loss attributable to controlling shareholders over the last four quarters (Q4 2025 to Q3 2026) is KRW 22.7 billion.

05

Industry analysis

Billions is classified under rubber products manufacturing, while its trading theme is listed as entertainment. As a result, the company runs two businesses on different cycles, manufacturing and content, under one corporate entity.

Condoms and gloves are manufacturing products whose economics depend on raw material prices and plant utilization. The description of the company as the top condom maker in the domestic market comes from the company's own profile.

Competition in entertainment sits between large listed talent agencies such as HYBE, SM Entertainment, JYP Entertainment, and YG Entertainment, and smaller production firms. Billions is a small-cap company that is hard to compare directly with the large listed agencies.

Drama and OTT production carries large earnings swings tied to hit rates, and other listed companies in the sector share that trait. Even within media and entertainment, Cheil Worldwide, CJ ENM, and Studio Dragon run different business models, so their results are hard to compare directly.

Whether the two consecutive annual revenue declines came from entertainment or from manufacturing can only be separated with segment data. Medical rubber products depend on healthcare institution demand and procurement conditions.

06

Outlook

The next periodic report will be the 2026 annual report, with a statutory filing deadline in late March 2027. That filing should fill in the annual figures for Q1 through Q3 2026, for which no quarterly net income attributable to controlling shareholders is yet available, and disclose segment sales.

The 2026 full-year operating result will be the first annual figure that can be compared with the KRW 834 million operating loss of 2025. The inside director election and articles amendment approved at the November 6 extraordinary meeting can be read as a possible turning point in management direction.

However, specific business plans do not yet appear in current disclosures. The reworded e-commerce business purpose keeps an online channel open as an option, but whether it is pursued will only become clear through later filings.

Quarterly revenue has declined since the largest shareholder changed in 2024, so whether the restructuring direction shows up in results is the next point to confirm. Whether production and management schedules in entertainment drive quarterly revenue swings can be checked with segment data.

With the medical device side at 45% of the Q2 2026 mix, demand in manufacturing also matters for the results direction. After a return to operating profit in Q1 2026, losses widened again in Q2 and Q3, so whether quarterly operating margins return to positive territory is the next key point to confirm.

07

Valuation

PER
—
PBR
0.4×
ROE
-63.2%
EPS
-₩4,329
BPS
₩5,974
Dividend per share
₩0

The price-to-book ratio sits below 1x, so the stock trades without a premium to book value. Because the combined net loss over the last four quarters has not turned positive, the price-to-earnings ratio cannot be calculated.

Looking at the annual record, losses attributable to controlling shareholders ran for four consecutive years from 2022 to 2025, while net income including non-controlling interests was positive in 2024. Shareholder returns through dividends have not been clearly visible.

Operating cash flow turned positive from 2024, but whether that holds while quarterly operating losses continue remains to be confirmed. The four-quarter net loss sits close in scale to equity, which limits how far book value can anchor the interpretation. The valuation reading will change depending on whether earnings recover.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Narrowing operating losses

The operating loss narrowed every year, from KRW 8.88 billion in 2022 to KRW 834 million in 2025. The operating margin improved from -11.4% to -3.3% over the same span. However, 2025 was slightly weaker than 2024 on margin.

Profit in Q1 2026

Operating profit of KRW 149 million in Q1 2026 marked a turn to profit, and that quarter's KRW 7.89 billion in revenue was the highest of the last five quarters. A quarter in profit is cited as evidence on the bull side. Operating losses returned in Q2 2026 at KRW 580 million.

Improved balance sheet and cash flow

The debt ratio fell from 121.8% in 2024 to 98.6% in 2025. Operating cash flow was positive at KRW 677 million in 2024 and KRW 722 million in 2025. The debt ratio falling below 100% reflects total liabilities at end-2025 being smaller than total equity.

09

Bear factors

Revenue and profit weakening together

Revenue fell over two consecutive quarters, to KRW 6.76 billion in Q2 2026 and KRW 4.84 billion in Q3 2026, and Q3 was down 36.2% year on year. The Q3 operating loss widened to KRW 1.04 billion. Operating losses have run for two consecutive quarters, Q2 and Q3 2026.

Cumulative losses against the equity base

Cumulative net losses are close to total equity, so further losses would directly affect the size of the equity base. The 2025 loss of KRW 7.13 billion was larger than the KRW 1.96 billion in 2024.

Quarterly net income for Q1 through Q3 2026 has not been confirmed in a periodic report, which makes the detailed trend hard to trace.

Governance and strategy in transition

The largest shareholder changed on May 21, 2024. At the November 6, 2026 extraordinary meeting, the election of Kim Tae-sung as an inside director and an articles amendment both passed.

Business direction and management composition are changing together, so the effect of the strategy shift on results will become visible in later filings.

10

Risk factors

Earnings persistence

Quarterly operating losses continued in Q2 and Q3 2026, and revenue fell for two consecutive quarters. The Q1 2026 profit was a single quarter, so the direction of quarterly results is hard to call. Because entertainment and medical device demand both feed into results, the causes need to be separated.

Capital and liquidity

The combined net loss over the last four quarters is KRW 22.7 billion, close to total equity of KRW 24.5 billion. With liabilities at KRW 24.2 billion, continued losses would erode capital headroom. Operating cash flow has been positive since 2024, but at its current scale it can offset losses only to a limited degree.

Governance and small-cap traits

After the largest shareholder changed in 2024, the board composition and articles were revised in November 2026. As a small-cap, the stock may see larger price swings and thinner trading liquidity.

Compared with large listed agencies in the sector, differences in resources and production capacity could affect the pace of expansion.

11

What to watch next

  1. Late March 2027

    Filing of the 2026 annual report. The missing quarterly net income attributable to controlling shareholders for Q1 through Q3 2026 will be filled in on an annual basis, and segment sales will be disclosed. The key point is how the 2026 full-year operating result compares with the KRW 834 million loss in 2025.

  2. Within Q1 2027 (release date not yet set)

    Announcement of Q4 2026 results. This is where to confirm whether quarterly operating profit returns to positive territory or the losses seen in Q2 and Q3 2026 continue.

  3. Date not yet set

    Disclosures on any e-commerce-related business launch following the articles amendment. These will show whether new activities feed into the revenue mix.

  4. Date not yet set

    Disclosures on management direction after the director appointment and on changes in largest-shareholder stakes. Whether the restructuring direction reverses the decline in quarterly revenue is the next point to confirm.

12

Overall view

Billions is a KOSDAQ company that combines condom and medical rubber manufacturing with entertainment. On a DART filing basis, the annual operating loss narrowed from KRW 8.88 billion in 2022 to KRW 834 million in 2025.

Revenue, however, peaked at KRW 97 billion in 2023 and then fell in both 2024 and 2025, and Q3 2026 revenue of KRW 4.84 billion was down 36.2% year on year. Q1 2026 showed an operating profit of KRW 149 million, but operating losses continued in Q2 and Q3 2026.

On the financial side, the debt ratio fell from 121.8% in 2024 to 98.6% in 2025, and operating cash flow was positive in both 2024 and 2025.

On the burden side are the combined KRW 22.7 billion net loss over the last four quarters, its relation to year-end 2025 equity of KRW 24.5 billion, and the changes in the largest shareholder and board since 2024.

On valuation, the price-to-book ratio sits below 1x and the price-to-earnings ratio cannot be calculated, so the reading depends heavily on whether earnings recover. The next point to confirm is the full-year result and segment sales in the 2026 annual report, due by late March 2027.

In short, the current filings show a tug-of-war between a narrowing annual loss and weakening quarterly results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.fnguide.com
  2. valueline.co.kr
  3. butler.works
  4. investing.com
  5. k5.co.kr
  6. digitaltoday.co.kr
  7. antwinner.com
  8. tradingkey.com
  9. tradingkey.com
  10. tradingkey.com
  11. datatooza.com
  12. tradingkey.com
  13. kr.investing.com
  14. kr.investing.com
  15. kr.investing.com
  16. kr.investing.com
  17. kr.investing.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis